Investigation Launched into Fulcrum Therapeutics Over SCD Drug Discontinuation
News related to:Fulcrum Therapeutics, Inc · 1 min read
Kaplan Fox & Kilsheimer LLP is currently investigating potential securities violations against Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for treating rare hematological disorders. The investigation follows a significant setback for the company, which announced the discontinuation of its pociredir program for the treatment of sickle cell disease (SCD) on June 1, 2026.
According to Fulcrum Therapeutics, the discontinuation was prompted by heightened concerns from the U.S. Food and Drug Administration (FDA). The FDA expressed concerns regarding the benefit-risk profile of pociredir, citing an unexpectedly high rate of secondary hematologic malignancies observed in the treatment of SCD. These concerns stemmed from the withdrawal of Tazverik® (tazemetostat), another PRC2 inhibitor, from the global market in March 2026. The FDA concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk, regardless of the specific subunit engaged.
As a result, Fulcrum Therapeutics has no viable regulatory path forward for further clinical development of pociredir. The company's stock price fell sharply following the announcement, declining from a closing price of $6.42 per share on June 1, 2026, to $3.14 per share on June 2, 2026. This represents a decline of $3.28 per share, or a 51.09% drop in value.
Fulcrum Therapeutics, Inc., is now facing scrutiny from Kaplan Fox & Kilsheimer LLP, a nationally recognized law firm with a long history of prosecuting complex securities litigation. Founded in 1956, the firm has recovered over $10 billion for clients and classes it has represented, including landmark cases such as the $2.425 billion recovery for Bank of America shareholders.
The investigation into Fulcrum Therapeutics is part of a broader effort to ensure that securities laws are upheld and that investors are protected from potential misconduct. Investors who have suffered losses or possess information that could assist in the investigation are encouraged to contact Kaplan Fox & Kilsheimer LLP.